WallStSmart

Celularity Inc (CELU)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Celularity Inc generates 3478% more annual revenue ($26.55M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

CELU

Avoid

18

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -16.06

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CELUUndervalued (+73.7%)

Margin of Safety

+73.7%

Fair Value

$4.68

Current Price

$1.02

$3.66 discount

UndervaluedFair: $4.68Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CELU1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.0710/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

CELU4 concerns · Avg: 2.8/10
Market CapQuality
$28.80M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-6367.0%2/10

ROE of -6367.0% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CELU

The strongest argument for CELU centers on Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CELU

The primary concerns for CELU are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

CELU is growing revenue faster at -77.4% — sustainability is the question.

CELU generates stronger free cash flow (-5M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVMD scores higher overall (24/100 vs 18/100). CELU offers better value entry with a 73.7% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Celularity Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Celularity Inc. is a forward-thinking biotechnology company focused on advancing regenerative medicine through its unique cellular products derived from the placenta. The company is advancing a comprehensive pipeline of innovative immunotherapies designed to provide allogeneic off-the-shelf solutions that enhance treatment effectiveness while reducing complications for cancer and other serious diseases. With a strong management team and strategic partnerships, Celularity aims to address significant unmet medical needs, positioning itself as a key player in the evolving field of advanced therapeutics.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?